Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G8UY
|
|||
| Former ID |
DNCL003128
|
|||
| Drug Name |
PF-04958242
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 2 | [1], [2] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H20N2O4S2
|
|||
| Canonical SMILES |
CC(C)S(=O)(=O)NC1COCC1OC2=CC=C(C=C2)C3=CC=C(S3)C#N
|
|||
| InChI |
1S/C18H20N2O4S2/c1-12(2)26(21,22)20-16-10-23-11-17(16)24-14-5-3-13(4-6-14)18-8-7-15(9-19)25-18/h3-8,12,16-17,20H,10-11H2,1-2H3/t16-,17+/m0/s1
|
|||
| InChIKey |
TTYKUKSFWHEBLI-DLBZAZTESA-N
|
|||
| CAS Number |
CAS 1258963-59-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glutamate receptor AMPA (GRIA) | Target Info | Activator | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.